NSE: GLENMARK | BSE: 532296

Expensive Underperformer

Download real time

1342.40 -14.40 (-1.06%)

26.68% Fall from 52W High

1.1M NSE+BSE Volume

NSE 17 Apr, 2025 3:31 PM (IST)

37,880.9

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Search Inside the pdf :

Glenmark Pharmaceuticals Ltd.

24 Dec 2024

1342.40

-1.06%

GLENMARK PHARMACEUTICALS

Accumulate: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Glenmark Pharmaceuticals Ltd. is trading below all available SMAs

Glenmark Pharmaceuticals Ltd.

19 Dec 2024

1342.40

-1.06%

Company Update:Glenmark Pharma.

Not Rated: Glenmark Pharmaceuticals Ltd.

Axis Direct

As the stock is not under our coverage, we do not offer a valuation. However, Glenmark pharmaceuticals is trading at 18x FY27 PE (Bloomberg Estimates).

Glenmark Pharmaceuticals Ltd. has lost -22.64% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

19 Dec 2024

1342.40

-1.06%

Company Update:Glenmark Pharma.

Not Rated: Glenmark Pharmaceuticals Ltd.

Axis Direct

As the stock is not under our coverage, we do not offer a valuation. However, Glenmark pharmaceuticals is trading at 18x FY27 PE (Bloomberg Estimates).

Glenmark Pharmaceuticals Ltd. is trading below all available SMAs

Glenmark Pharmaceuticals Ltd.

18 Nov 2024, 12:00AM

1342.40

-1.06%

Key therapy areas continue to perform aid profitability

Buy: Glenmark Pharmaceuticals Ltd.

KRChoksey

Glenmark Pharma’s revenue was largely in-line with our estimates due to strong growth in India and Europe. However, EBITDA missed our estimates due to higher-than-expected employee expenses and other expenses.

Glenmark Pharmaceuticals Ltd. is trading below all available SMAs

Glenmark Pharmaceuticals Ltd.

20 Aug 2024

1342.40

-1.06%

Stable outlook with new product launches and market expansion strategies

Buy: Glenmark Pharmaceuticals Ltd.

Target

KRChoksey

Glenmark Pharma’s revenue and EBITDA was in-line with our estimate where Adj. PAT beat our estimate due to lower-than-expected depreciation expense.
We believe the upcoming launches of Ryaltris in multiple new markets and the anticipated filing of Envafolimab in over 20 markets are expected to provide a future boost.

Glenmark Pharmaceuticals Ltd. has lost -22.64% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

16 Aug 2024

1342.40

-1.06%

India traction improving; co maintains FY25 guidance

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark Pharmaceuticals’ (Glenmark) Q1FY25 result was driven by better traction in India (+12% YoY) and EU (+21%) and lower R&D (-190bps).

Glenmark Pharmaceuticals Ltd. has gained 26.64% in the last 1 Year

Glenmark Pharmaceuticals Ltd.

16 Aug 2024

1342.40

-1.06%

Operationally in-line 1Q; DF/EU drive earnings

Buy: Glenmark Pharmaceuticals Ltd.

Recommendation Target

Motilal Oswal

Glenmark Pharma (GNP) delivered an in-line operating performance in 1QFY25. It witnessed robust traction in the domestic formulation (DF) and Europe businesses.

Glenmark Pharmaceuticals Ltd. is trading below all available SMAs

Glenmark Pharmaceuticals Ltd.

18 Jun 2024, 12:00AM

1342.40

-1.06%

GLENMARK PHARMACEUTICALS

Hold: Glenmark Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Glenmark Pharmaceuticals Ltd. is trading below all available SMAs

Glenmark Pharmaceuticals Ltd.

03 Jun 2024

1342.40

-1.06%

India business has a strong growth trajectory

Buy: Glenmark Pharmaceuticals Ltd.

Target

KRChoksey

EBITDA beat our estimate due to improved products and geographical mix.
The stock is trading at 24.9x/19.4x based on FY25E/FY26E EPS respectively.

Glenmark Pharmaceuticals Ltd. has gained 26.64% in the last 1 Year

Glenmark Pharmaceuticals Ltd.

27 May 2024

1342.40

-1.06%

Operating performance above est.; FY25 outlook better

Neutral: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

pairment of INR23b
? Glenmark Pharma (GNP) posted lower-than-expected revenue in 4QFY24.
However, it delivered better-than-expected profitability for the quarter,
aided by an improved product mix and lower raw material costs. Having said
this, GNP has taken a considerable impairment charge on manufacturing
facilities and certain intangibles (~INR32b) during the quarter

Glenmark Pharmaceuticals Ltd. has lost -22.64% in the last 6 Months

Is Glenmark Pharmaceuticals Ltd. worth buying?

558 Votes:

Buy 79.21%

Sell 13.62%

Hold 7.17%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Not Rated SEE REPORTS >

pdf